-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT ANNOUNCES PHASE 3 CREDIT-5 STUDY MET PRIMARY ENDPOINT, SINTBILO® (TAFOLECIMAB INJECTION) AS FIRST-LINE MONOTHERAPY TREATMENT FOR HYPERLIPIDEMIA DEMONSTRATED POTENT LIPID-LOWERING EFFICACY

Reuters·11/09/2026 00:00:00

Please log in to view news